Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company (BMY) is dated October 30, 2019. The report addresses Item 8.01 (Other Events) regarding the extension of expiration dates for specific debt exchange offers and consent solicitations related to Celgene Corporation notes.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios. The only financial figure disclosed relates to the aggregate principal amount of notes involved in the exchange offer:
- Celgene Notes Subject to Exchange: Up to $19,850,000,000 aggregate principal amount.
Material Changes
The primary material change reported is the extension of the expiration date for the Exchange Offers and Consent Solicitations:
- Previous Expiration Date: October 31, 2019, at 5:00 p.m. New York City time.
- New Expiration Date: November 4, 2019, at 5:00 p.m. New York City time.
- Future Extensions: The company noted the expiration date may be further extended one or more times, with advance notice provided.
Guidance, Outlook, and Management Commentary
Management commentary focuses on the status of the planned acquisition of Celgene (the "Merger") and the associated debt restructuring:
- Merger Timeline: The closing of the Merger is expected to occur by the end of 2019.
- Settlement Timing: Settlement of the Exchange Offers is expected to occur promptly after the Expiration Date and on or about the Merger closing date.
- Conditions: The Exchange Offers and Consent Solicitations are conditioned upon the closing of the Merger, a condition that cannot be waived by Bristol-Myers Squibb.
- Amendments: The process involves adopting amendments to eliminate substantially all restrictive covenants and certain events of default in the indentures governing the Celgene Notes.
Investor Verification Checklist
- Verify the final closing date of the Celgene Merger to confirm if it occurs by the end of 2019 as expected.
- Monitor for further press releases regarding additional extensions of the Exchange Offer expiration date beyond November 4, 2019.
- Confirm the final settlement date of the Exchange Offers once the Merger closes.
- Review the confidential offering memorandum and consent solicitation statement (dated April 17, 2019, as amended) for specific terms of the new notes and cash consideration.